ValuEngine cut shares of Cellectis (NASDAQ:CLLS) from a hold rating to a sell rating in a research note published on Friday morning.
Other equities analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Cellectis from a buy rating to a hold rating in a report on Thursday, November 16th. Jefferies Group restated a buy rating and set a $47.00 price target on shares of Cellectis in a report on Sunday, October 29th. SunTrust Banks restated a hold rating and set a $20.00 price target on shares of Cellectis in a report on Friday, October 6th. Nomura lowered their price target on shares of Cellectis from $49.00 to $43.00 and set a buy rating on the stock in a report on Wednesday, September 6th. Finally, Wells Fargo & Company restated an outperform rating and set a $40.00 price target (up from $33.00) on shares of Cellectis in a report on Tuesday, September 5th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. Cellectis currently has a consensus rating of Hold and a consensus price target of $39.29.
Cellectis (NASDAQ:CLLS) opened at $23.70 on Friday. Cellectis has a 52-week low of $16.32 and a 52-week high of $35.07.
Institutional investors have recently bought and sold shares of the company. ARK Investment Management LLC grew its holdings in shares of Cellectis by 79.1% during the 2nd quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 1,784 shares in the last quarter. Williams Jones & Associates LLC bought a new stake in Cellectis in the second quarter worth $244,000. Wells Fargo & Company MN boosted its holdings in Cellectis by 132.1% in the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 5,435 shares in the last quarter. KBC Group NV bought a new stake in Cellectis in the third quarter worth $366,000. Finally, JPMorgan Chase & Co. bought a new stake in Cellectis in the third quarter worth $517,000. Institutional investors and hedge funds own 16.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Cellectis (CLLS) Rating Lowered to Sell at ValuEngine” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/05/cellectis-clls-rating-lowered-to-sell-at-valuengine.html.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cellectis SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis SA and related companies with MarketBeat.com's FREE daily email newsletter.